{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:56:40Z","timestamp":1792205800736,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biomaterials.2025.123216","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:54:48Z","timestamp":1740538488000},"page":"123216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Immunity\/metabolism dual-regulation via an acidity-triggered bioorthogonal assembly nanoplatform enhances glioblastoma immunotherapy by targeting CXCL12\/CXCR4 and adenosine-A2AR pathways"],"prefix":"10.1016","volume":"319","author":[{"given":"Ruili","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunfeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengsheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-9429","authenticated-orcid":false,"given":"Ruimeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 world health organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123216_bib2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3174\/ajnr.A8225","article-title":"Molecular gbm versus histopathological gbm: radiology-pathology-genetic correlation and the new who 2021 definition of glioblastoma","volume":"45","author":"Agarwal","year":"2024","journal-title":"Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123216_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cai2.59","article-title":"Progress in phase iii clinical trials of molecular targeted therapy and immunotherapy for glioblastoma","volume":"2","author":"Wang","year":"2023","journal-title":"Cancer Innov"},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123216_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5306\/wjco.v14.i4.138","article-title":"Immunotherapy in glioblastoma treatment: current state and future prospects","volume":"14","author":"Rocha","year":"2023","journal-title":"World J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123216_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1158\/1078-0432.CCR-21-2681","article-title":"Designing clinical trials for combination immunotherapy: a framework for glioblastoma","volume":"28","author":"Singh","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123216_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.annonc.2022.11.008","article-title":"Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy","volume":"34","author":"White","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123216_bib8","article-title":"Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy","volume":"2","author":"Ding","year":"2022","journal-title":"Exploration (Beijing)"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123216_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123216_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2020.01.027","article-title":"Glioblastoma precision therapy: from the bench to the clinic","volume":"475","author":"Zhou","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biomaterials.2025.123216_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and chemokine receptors: new targets for cancer immunotherapy","volume":"10","author":"Mollica","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123216_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122983","article-title":"Advances in chemokine signaling pathways as therapeutic targets in glioblastoma","volume":"13","author":"Urbantat","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2025.123216_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.actbio.2024.02.007","article-title":"Nanoparticle-mediated blockade of cxcl12\/cxcr4 signaling enhances glioblastoma immunotherapy: monitoring early responses with mri radiomics","volume":"177","author":"Wei","year":"2024","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123216_bib15","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant cxcr4-cxcl12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123216_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/anie.201804882","article-title":"Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy","volume":"58","author":"Duan","year":"2019","journal-title":"Angew. Chem.-Int. Edit."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/tj.5000675","article-title":"The inducers of immunogenic cell death for tumor immunotherapy","volume":"104","author":"Li","year":"2018","journal-title":"Tumori J."},{"key":"10.1016\/j.biomaterials.2025.123216_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biomaterials.2025.123216_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-060619-023155","article-title":"Inhibition of the adenosine pathway to potentiate cancer immunotherapy: potential for combinatorial approaches","volume":"72","author":"Thompson","year":"2021","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123216_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020229","article-title":"Adenosinergic pathway: a hope in the immunotherapy of glioblastoma","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"issue":"26","key":"10.1016\/j.biomaterials.2025.123216_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2025.123216_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.actbio.2019.09.009","article-title":"Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review","volume":"101","author":"Thakkar","year":"2020","journal-title":"Acta Biomater."},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123216_bib23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of fda-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123216_bib24","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1021\/acs.accounts.9b00228","article-title":"Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures","volume":"52","author":"He","year":"2019","journal-title":"Accounts Chem. Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123216_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biomaterials.2025.123216_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115184","article-title":"Drugs targeting adenosine signaling pathways: a current view","volume":"165","author":"Kutryb-Zajac","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123216_bib27","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"Cxcr4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"28","key":"10.1016\/j.biomaterials.2025.123216_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba6156","article-title":"Detection of response to tumor microenvironment-targeted cellular immunotherapy using nano-radiomics","volume":"6","author":"Devkota","year":"2020","journal-title":"Sci. Adv."},{"issue":"22","key":"10.1016\/j.biomaterials.2025.123216_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clon.2016.09.015","article-title":"Radiotherapy in glioblastoma: the past, the present and the future","volume":"29","author":"Gzell","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2025.123216_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693146","article-title":"Irradiation-modulated murine brain microenvironment enhances gl261-tumor growth and inhibits anti-pd-l1 immunotherapy","volume":"11","author":"Garbow","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijrobp.2018.08.033","article-title":"Late effects of radiation prime the brain microenvironment for accelerated tumor growth","volume":"103","author":"Duan","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Pt 2","key":"10.1016\/j.biomaterials.2025.123216_bib34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biomaterials.2025.123216_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017742575","article-title":"Radiation effects on antitumor immune responses: current perspectives and challenges","volume":"10","author":"Walle","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123216_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: a synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med. J. Aust."},{"issue":"34","key":"10.1016\/j.biomaterials.2025.123216_bib37","doi-asserted-by":"crossref","first-page":"23001","DOI":"10.1021\/acsnano.4c04553","article-title":"Boost infiltration and activity of t cells via inhibiting ecto-5'-nucleotidase (cd73) immune checkpoint to enhance glioblastoma immunotherapy","volume":"18","author":"Zhang","year":"2024","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123216_bib38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","article-title":"Metabolic and epigenetic regulation of t-cell exhaustion","volume":"2","author":"Franco","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.biomaterials.2025.123216_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715234","article-title":"Cd8(+) t cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123216_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted cd8(+) t cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123216_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","article-title":"T cell exhaustion in malignant gliomas","volume":"9","author":"Watowich","year":"2023","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123216_bib42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of t cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:34:05Z","timestamp":1741584845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961225001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["S0142961225001358"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123216","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunity\/metabolism dual-regulation via an acidity-triggered bioorthogonal assembly nanoplatform enhances glioblastoma immunotherapy by targeting CXCL12\/CXCR4 and adenosine-A2AR pathways","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123216"}}